Technology

Cytovation’s CyPep-1 specifically targets wart cells, lysing the cell membranes and inducing rapid cell death.

Targeting Wart Cells

Based on recent findings, Cytovation believes that CyPep-1 will not only reduce the size of papillomas, but also has the potential to stimulate the immune system through the destruction of the cell membrane and the release of viral antigens, leading to permanent regression. As such, this is a completely novel treatment strategy to treat a common disease, which has applications in other dermatological diseases.

Technology Platform

CyPep-1 is a Novel Treatment for a Common Disease

CyPep-1 is a peptide with a novel mechanism that selectively targets and lyses skin tumour cells due to a negative charge on cell membranes not found on healthy cells.

By actively destroying the cell membrane, CyPep-1 will not only reduce the size of warts but is also able to stimulate the immune system through the release of viral antigens, potentially leading to permanent regression. As such, this is a completely novel treatment strategy for a very common disease that currently has no approved prescription treatment. CyPep-1 is currently in pre-clinical development for the treatment of warts but it also has applications in other dermatological disorders.

Background on CyPep-1

Proprietary peptide consisting of 27 amino acids

Novel mechanism that selectively targets and destroys skin tumour cells/warts

The release of antigens from lysed cells has been shown to stimulate the immune system and could lead to long-term ‘protection’

Currently in pre-clinical development following extensive testing and quality controls

Patents

CyPep-1 has claims granted both to the peptide itself and to specific medical uses of the peptide across Europe and USA.